TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06144463

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lung ultrasound-guided fluid resuscitation
Description: For the LUGFR group, therapy was applied based on the same treatment guidelines, and initial lung ultrasonography was performed after enrollment as baseline assessment of lung. The lung ultrasound was conducted using the Doppler ultrasound diagnostic instrument (Philips CX50) at a probe frequency range of 8 to 12 MHz. Lung ultrasonography was conducted using the 12-region method that included the anterior, lateral, and posterior walls on both sides of the lung, which was focused on the condition of A-lines, B-lines (including confluent B-line and compact B-lines), lung consolidation and pleural effusion

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: lung ultrasound-guided fluid resuscitation
Description: For the LUGFR group, therapy was applied based on the same treatment guidelines, and initial lung ultrasonography was performed after enrollment as baseline assessment of lung. The lung ultrasound was conducted using the Doppler ultrasound diagnostic instrument (Philips CX50) at a probe frequency range of 8 to 12 MHz. Lung ultrasonography was conducted using the 12-region method that included the anterior, lateral, and posterior walls on both sides of the lung, which was focused on the condition of A-lines, B-lines (including confluent B-line and compact B-lines), lung consolidation and pleural effusion
Study: NCT06427408

Intervention type: OTHER
Intervention: Non applicable
Description: Placental transcriptomic analysis
Study: NCT05269160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermaprazole 1%
Description: Dermaprazole cream at a concentration of 1% will be applied to the irradiated area twice daily for up to 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermaprazole 1%
Description: Dermaprazole cream at a concentration of 1% will be applied to the irradiated area twice daily for up to 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermaprazole 2%
Description: Dermaprazole cream at a concentration of 2% will be applied to the irradiated area twice daily for up to 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermaprazole 2%
Description: Dermaprazole cream at a concentration of 2% will be applied to the irradiated area twice daily for up to 7 weeks
Study: NCT04954404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcatheter mitral valve repair/transcatheter mitral valve replacement
Description: transcatheter mitral valve repair/transcatheter mitral valve replacement
Study: NCT06436118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RELAX® glasses
Description: Glasses which are a solution of audiovisual sedation by positive distraction for hospital medical use.
Study: NCT06262308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological intervention along Cognitive Behavioural Therapy principles
Description: Women who have PPROM will be offered a series of 6 sessions with a Clinical Psychologist
Study: NCT05294315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bi-level erector spinae block
Description: erector spinae block at 4th and 6th transverse process

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single level erector spinae block
Description: erector spinae block at 4th transverse process
Study: NCT05829954

Intervention type: OTHER
Intervention: questionnaire
Description: All questionnaire were obtained via online survey system.

Intervention type: OTHER
Intervention: questionnaire
Description: All questionnaire were obtained via online survey system.

Intervention type: OTHER
Intervention: questionnaire
Description: All questionnaire were obtained via online survey system.
Study: NCT05762497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moldable adhesive
Description: Patients were provided with the new adhesives and a short questionnaire on current ASV use. After a week, they were contacted by telephone to verify any doubts/problems. At the end of the two weeks, the patient was again administered a questionnaire to evaluate the new moldable adhesive (while using the ASV).
Study: NCT06426953

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05715164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E-cigarettes device plus liquid
Description: The four basic care counseling sessions will be held over the course of 48 weeks with the supply of e-cigarettes and liquid. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health as well as any side effects from using e-cigarettes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Pouches
Description: The four basic care counseling sessions will be held over the course of 48 weeks with a supply of nicotine pouches. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health as well as any side effects from using nicotine pouches.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic care counseling about smoking cessation
Description: The four basic care counseling sessions will be held over the course of 48 weeks. Every 12 weeks, a standard care counseling session will be offered, and it will be followed by a study visit to track any alterations in the user's physical or mental health.
Study: NCT05772819

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: exercise MRI
Description: All patients are subjected to two types of in-magnet exercise tests consisting of exercise cardiac magnetic resonance imaging (exCMR) and Phosphorus 31 magnetic resonance spectrography (31P MRS) of the quadriceps muscle, during exercise at various exercise intensities in a supine position using a MR-compatible ergometer (Lode MR Ergometer Pedal, Lode BV, Groningen, the Netherlands).
Study: NCT06166940

Intervention type: OTHER
Intervention: ROTEM Guided Management
Description: ROTEM guided management of hemostasis after CPB
Study: NCT06532396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QRL-101
Description: Multiple-ascending doses of QRL-101 will be orally administered. The dose levels may change subject to available nonclinical, clinical, safety, and PK data.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple-ascending doses of comparator placebo will be administered orally to healthy participants.
Study: NCT05205187

Intervention type: PROCEDURE
Intervention: Healthy control specimen collection
Description: Collecting blood and feces from healthy population.

Intervention type: PROCEDURE
Intervention: Non-Borrmann IV patient specimen collection
Description: Collecting blood, feces and gastric cancer tissues from Non-Borrmann IV patients.

Intervention type: PROCEDURE
Intervention: Borrmann IV patient specimen collection
Description: Collecting blood, feces and gastric cancer tissues from Borrmann IV patients.
Study: NCT05857644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07923568
Description: One time dose of 4 capsules taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07923568
Description: One time dose of 4 capsules taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07923568
Description: One time dose of 4 capsules taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07923568
Description: One time dose of 4 capsules taken orally.
Study: NCT06298240

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nursing procedure for acute health problems of low complexity
Description: An agreed nursing procedure is applied for users of a primary care emergency center who spontaneously consult for 5 acute health problems of low complexity: gastroenteritis, cystitis in women, dental pain, upper respiratory tract affections and acute wounds
Study: NCT05206175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Affect Treatment Program for Methamphetamine Use Disorder
Description: Telemedicine based group and individual therapy, drug screens, contingency management, therapeutic app engagement, psychiatric interventions for adjuvant medications.
Study: NCT04237025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nordic walking exercise
Description: Supervised Nordic Walking (NW) exercise will be conducted in a small group setting with a 2:1 participant to trainer ratio providing individualized training instruction. Training will be conducted for a total of 14 one-hour sessions over a 6-week period. Training will take place at an outdoor community track with progression tasks on hills or grassy terrain. The one-hour training sessions will include a 10-minute warm-up period, 45 minutes of individualized NW training, and a 5-minute cool down period. The target training duration goal for NW exercise will be 45 minutes of continuous walking at moderate intensity based on target heart rate and Rating of Perceived Exertion. NW exercise program will be customized and progressed for each participant by trainers with ongoing assessment of participant's gait pattern, NW technique, and exercise responses during the training sessions. Group comradery and accountability will be facilitated through training in small group training context.
Study: NCT05470049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR8554 Injection and SHR0410 Injection
Description: Treatment group A: SHR8554 Injection and SHR0410 Injection; high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR8554 Injection and SHR0410 Injection
Description: Treatment group B: SHR8554 Injection and SHR0410 Injection; low dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR8554 Injection and Placebo for SHR0410 Injection
Description: Treatment group C: SHR8554 Injection and Placebo for SHR0410 Injection
Study: NCT06115629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveillance protocol
Description: Imaging surveillance will entail a computed tomography scan of the chest, abdomen and pelvis, as well as clinical review, every 6 months for 36 months post surgery along with an endoscopy at 12 months post surgery.
Study: NCT05630820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepirovirsen
Description: Bepirovirsen will be administered.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered.
Study: NCT05199415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health and Well-being Committee
Description: Health and Well-being Committees (HaWCs) will be introduced in treatment sites as a means to facilitate on-going problem identification and collaborative processes for developing action plans, implementing small-scale, site-based improvements. HaWCs will involve 10-14 workers and frontline supervisors, with a worker and manager co-chair. HaWCs will identify challenges to safety, health, and well-being spanning physical hazards, COVID-19 protocols as relevant, other conditions of work (e.g., schedules, pace of work), and policies (e.g., absenteeism, performance management). They will then design and implement mitigating solutions and track outcomes. As such, HaWCs have a broader scope than traditional safety committees and will actively solicit worker voice regarding policies and practices that are not labeled as health and safety policies.
Study: NCT05732051

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Riboside
Description: Nicotinamide Riboside 500mg b.i.d as long as the patient is receiving anthracycline therapy

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo b.i.d as long as the patient is receiving anthracycline therapy
Study: NCT05952687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Patients will receive idasanutlin dosed once daily on Days 1-5 of a 28-day cycle starting with 80% of the RP2D determined in the ongoing pediatric iMATRIX trial using single agent idasanutlin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Patients will receive idasanutlin dosed once daily on Days 1-5 of a 28-day cycle starting with the RP2D determined in the dose-finding/safety phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Patients will receive idasanutlin dosed once daily on Days 1-5 of a 28-day cycle starting with the RP2D determined in the dose-finding/safety phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Patients will receive idasanutlin dosed once daily on Days 1-5 of a 28-day cycle starting with the RP2D determined in the dose-finding/safety phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Patients will receive selinexor on Day 4 of each of the first 3 weeks of a 28-day cycle. Selinexor will be skipped on week 4 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Patients will receive selinexor on Day 4 of each of the first 3 weeks of a 28-day cycle. Selinexor will be skipped on week 4 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Patients will receive selinexor on Day 4 of each of the first 3 weeks of a 28-day cycle. Selinexor will be skipped on week 4 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Patients will receive selinexor on Day 4 of each of the first 3 weeks of a 28-day cycle. Selinexor will be skipped on week 4 of each cycle.
Study: NCT05978973

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elemental Diet
Description: . Elemental diets contain all daily required vitamins, micronutrients and macronutrients. The ingredients are readily digestible (carbohydrates, amino acids and medium chain fatty acids) and are absorbed within the proximal small bowel. One main disadvantage of elemental diets such as Vivonex is their unpalatability3 which has limited their use.
Study: NCT04929405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADAPT
Description: ADAPT, is multi-modal to promote a targeted approach to individual parental bereavement experiences and is not time or geographically limited. ADAPT is based on the theoretical foundations of the Adaptive Leadership (AL) framework. Our interdisciplinary team developed a web-based, multi-modal intervention, labeled ADAPT, that incorporates varied self-management strategies including: A: Asking for assistance (option to connect with child's healthcare team); DA: Developing Adaptive ability (self-management tools: e.g. stress reduction, legacy building); P: Accessing Pertinent online resources (grief support networks/websites); and T: Tracking one's health (self-administered surveys for grief, sleep, anxiety, and depression). Parents can download ADAPT on any digital device (phones/computers) using a Quick Response (QR) bar code or weblink.
Study: NCT04997447

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-reduction/Exercise Rehab
Description: 2-week limited daily steps (\<2000), and then 4 weeks of typical strength+endurance exercise for older adults
Study: NCT04998760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-008
Description: ATG-008 will be orally administered at 30 mg QD combined with chemotherapies. And about 8-12 subjects plan in each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-010
Description: ATG-010 will be orally administered at 30 mg QD and 80 mg QW combined with chemotherapies. And about 8-12 subjects plan in each cohort.
Study: NCT05851703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy application
Description: In lower cervical lateral flexion problems, pushing technique will be applied with instrument support from the articular pillar part of the superior vertebra on the side where the limitation is present.~In lower cervical lateral flexion problems, instrument-assisted pushing technique will be applied from the articular pillar part of the superior vertebra on the side where the limitation is present.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation
Description: With the rhythmic initiation technique, it is to teach the movement to the person, to improve the feeling of movement, coordination and to help relaxation. With rhythmic initiation, we want the patient's initial passive and then active participation to understand the movement, the direction and rhythm of the movement. After people actively participate, they can use active joint movement.
Study: NCT05446233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] Antaitavir Hasophate
Description: 100 mg suspension containing 200µCi of \[14C\] Antaitavir Hasophate
Study: NCT06261801

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication Group
Description: Participants in the medication group would take 150-mg pregabalin capsules (manufactured by Pfizer Pharmaceuticals Co., Ltd) orally twice daily (total daily dose, 300 mg) for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EA Group
Description: Acupoints selection: Ashi acupoint, Sibai acupoint (ST2), Xiaguan acupoint (ST7), and Dicang acupoint (ST4) on the affected side. Acupoints for the diseased branches (all taken from the affected side): eye branch and Tongziliao point (GB1), the maxillary branch is taken from the Quanliao point (SI18), and the mandibular branch is taken from the Jiache point (ST6).Shenting point (DU24), Baihui point (DU20), Hegu point (LI4), Waiguan point (TE5), Yanglingquan point (GB34), and Taichong point (LR3) on the affected side Operation: The EA apparatus will be applied on the Ashi point and (LI4 - TE5). The treatment will last for 30 minutes and the electrical stimulation will be set as 2/100Hz in frequency.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EA+Medication Group
Description: Participants in the EA+Medication group would receive both EA and medical treatement. The acupoints and their location, needles, the settings of the EA device are the same as EA Group's; in the meanwhile, the medication and its dosage is the same as Medication Group's.
Study: NCT05225727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Me & You - Tech
Description: The 13 MYT lessons will train youth to adopt a zero tolerance approach to dating violence (DV) and contain activities to enable youth to recognize healthy (non-abusive) and unhealthy (abusive) relationships, assess their own relationships, and adopt and practice a lifestyle paradigm of select-detect-protect informed by SCT self-regulatory frameworks. Within this lifestyle paradigm, youth select their personal rules to have only healthy (non-abusive) relationships, detect unhealthy (abusive) relationships that might threaten their rules, and learn to protect their rules using communication, management, and avoidance skills. MYT will tailor content by gender, relationship status, and the youth's DV profile of perpetration or victimization based on the Conflict in Adolescent Dating and Relationship Inventory (CADRI).
Study: NCT05258604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: argon plasma coagulation
Description: APC Standard APC equipment will be used, consisting of a high-frequency electrosurgical generator (ICC 350; ERBE, Tübingen, Germany), an argon source which is regulated automatically (APC 300) and APC probe.
Study: NCT06610721

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Biomarkers
Description: At baseline midstream urine will be collected in a sterile urine container.
Study: NCT06349746

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic exercises
Description: stretching exercise to posterior capsule and progressive resistance exercise for rotator cuff and scapula stabilizer and home exercise 3 sessions per week for 6 week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mobilization exercise
Description: cervical unilateral antero-posterior mobilization and thoracic central postro-anterior mobilization
Study: NCT06242860

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELM
Description: Treatment of dry eye with ELM device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELM
Description: Treatment of dry eye with ELM device
Study: NCT06055348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC0191
Description: SC0191 PO will be taken on days 1-3, 8-10, and 15-17 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC0191
Description: SC0191 PO will be taken on days 1-3, 8-10, and 15-17 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
Study: NCT05356299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetictape bandage application
Description: The Magnetic Tape bandage will be placed by the patient's care team and will be placed in the anterior superior part of each hemithorax, matching the large vessels and lymph nodes, in the posterior part of the thorax in the paravertebral area from C3 to T9 and in the subcostal region, following the direct innervation of the thorax and shoulder girdle, as well as the dorsal levels with lateral horns that control the vascularisation of the thorax and shoulder girdle.
Study: NCT04744168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Puncture of 5 points 4GI, 6RP, 34VB, 36E, 3F

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acupuncture
Description: Puncture of point HM
Study: NCT04444973

Intervention type: PROCEDURE
Intervention: Balloon pulmonary angioplasty
Description: Balloon dilatation of sub segmental pulmonary artery web disease